Nov 4 (Reuters) - Sana Biotechnology Inc :
* SANA BIOTECHNOLOGY ANNOUNCES INCREASED FOCUS ON TYPE 1 DIABETES AND B-CELL MEDIATED AUTOIMMUNE DISEASES WITH THE POTENTIAL TO DELIVER CLINICAL PROOF OF CONCEPT DATA ACROSS MULTIPLE STUDIES IN 2024 AND 2025
* SANA BIOTECHNOLOGY INC - TO PRIORITIZE SC291 IN B-CELL MEDIATED AUTOIMMUNE DISEASES
* SANA BIOTECHNOLOGY INC - SUSPENDS DEVELOPMENT OF SC291 IN ONCOLOGY AND SC379
* SANA BIOTECHNOLOGY INC - 2024 OPERATING CASH BURN MAY EXCEED $200 MILLION
* SANA BIOTECHNOLOGY INC - HALTS ENROLLMENT IN SC291 ONCOLOGY TRIAL
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。